Bibliografia sulle Strategie antivirali contro il virus Ebola

1. Sanchez, A.; Khan, A. S.; Zaki, S. R.; Nabel, G. J.; Ksiazek, T. G.; et al. Filoviridae. In
Fields Virology, Lippincott, Williams, & Wilkins, Philadelphia, 2001, pp. 1279–1304.

2. Johnson, K. M.; Lange, J. V.; Webb, P. A.; Murphy, F. A. Isolation and partial
characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet
1977, i, 569–571.
3. Peters, C. J.; Khan, A. S. Filovirus diseases. Curr. Top. Microbiol. Immunol. 1999, 235,
85–95.
4. Jahrling, P. B.; Geisbert, T. W.; Dalgard, D. W.; Johnson, E. D.; Ksiazek, T. G.; et al.
Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet
1990, 335, 502–505.
5. Johnson, E.; Jaax, N.; White, J.; Jahrling, P. Lethal experimental infections of rhesus
monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 1995, 76, 227–236.
6. Jaax, N.; Jahrling, P.; Geisbert, T.; Geisbert, J.; Steele, K.; et al. Transmission of Ebola
virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory [see
comments]. Lancet 1995, 346, 1669–1671.
7. Belanov, E. F.; Muntianov, V. P.; Kriuk, V. D.; Sokolov, A. V.; Bormotov, N. I.; et al.
Survival of Marburg virus infectivity on contaminated surfaces and in aerosols. Vopr.
Virusol. 1996, 41, 32–34.
8. Feldmann, H.; Klenk, H.-D. Marburg and Ebola viruses. Adv. Virus Res. 1996, 47, 1–52.
9. Bray, M. Filoviridae. In Clinical Virology, 2nd ed., ASM Press, Washington, DC, 2002,
pp. 875–890.
10. Colebunders, R.; Borchert, M. Ebola haemorrhagic fever—a review. J. Infect. 2000, 40,
16–20.
11. Rotz, L.; Khan, A.; Lillibridge, S.; Ostroff, S.; Hughes, J. Public health assessment of
potential biological terrorism agents. Emerging Infect. Dis. 2002, 8, 225–229.
12. Borio, L.; Inglesby, T.; Peters, C. J.; et al. Hemorrhagic fever viruses as biological
weapons—medical and public health management. JAMA 2002, 287, 2391–2405.
13. Alibek, J.; Handelman, S. Biohazard, Random House, New York, 1999.
14. Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57,
53–60.
15. Volchkov, V. E.; Chepurnov, A. A.; Volchkova, V. A.; Ternovoi, V. A.; Klenk, H.-D.
Molecular characterisation of guinea pig-adapted variants of Ebola virus. Virology 2000,
277, 147–155.
16. Hart, M. K. Vaccine research efforts for filoviruses. Int. J. Parasitol. 2003, 33, 583–595.
17. Parren, P.W. H. I.; Geisbert, T.W.; Maruyama, T.; Jahrling, P. B.; Burton, D. R. Pre- and
postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer
of a neutralizing human antibody. J. Virol. 2002, 76, 6408–6412.
18. Geisbert, T. W.; Pushko, P.; Anderson, K.; Smith, J.; Davis, K. J.; et al. Evaluation in
nonhuman primates of vaccines against Ebola virus. Emerging Infect. Dis. 2002, 8, 503–
507.
19. Mupapa, K.; Massamba, M.; Kibadi, K.; Kuvula, K.; Bwaka, A.; et al. Treatment of Ebola
hemorrhagic fever with blood transfusions from convalescent patients. International
Scientific and Technical committee. J. Infect. Dis. 1999, 179 (Suppl. 1), 18–23.
20. Sadek, R. F.; Khan, A. S.; Stevens, G.; Peters, C. J. Ebola hemorrhagic fever, Democratic
Republic of Congo, 1995: determinants of survival. J. Infect. Dis. 1999, 179 (Suppl. 1),
S24–27.

21. Jahrling, P. B.; Geisbert, T. W.; Geisbert, J. B.; Swearengen, J. R.; Bray, M.; et al.
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of
experimental Ebola virus infections. J. Infect. Dis. 1999, 179 (Suppl. 1), S224–234.
22. Hevey, M.; Negley, D.; Geisbert, J.; Jahrling, P. B.; Schmaljohn, A. Antigenicity and
vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants.
Virology 1997, 239, 206–216.
23. Jahrling, P. B.; Geisbert, J.; Swearengen, J. R.; Jaax, G. P.; Lewis, T.; et al. Passive
immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from
hyperimmune horses. Arch. Virol. Suppl. 1996, 11, 135–140.
24. Kudoyarova-Zubavichene, N. M.; Sergeyev, N. N.; Chepurnov, A. A.; Netesov, S. V.
Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus
infections. J. Infect. Dis. 1999, 179 (Suppl. 1), S218–223.
25. Gupta, M.; Mahanty, S.; Bray, M.; Ahmed, R.; Rollin, P. E. Passive transfer of antibodies
protects immunocompetent and immunodeficient mice against lethal Ebola virus
infection without complete inhibition of viral replication. J. Virol. 2001, 75, 4649–
4654.